The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
The second primary end point of medically attended, RSV-associated LRTI revealed that the RSVpreF vaccine was 57.1% effective (99.5% CI, 14.7%-79.8%), but these results were not statistically significant.16 Since the trial was conducted during the height of the COVID-19 pandemic when more mi...
[03:30.96]In May, the FDA approved two RSV vaccines for older adults [03:37.36]from GlaxoSmithKline and Pfizer. [03:41.84]In August, the FDA is expected to make a decision [03:46.36]on approving Pfizer's vaccine for pregnant wo...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the companysaid Friday, making it the first shot greenlit for use in this age group to guard against RSV. Global...
第1892期:New RSV Vaccine Approved for Children 2023-07-24 08:00:0003:56 8459 所属专辑:英语每日一听 | 每天少于5分钟 喜欢下载分享 声音简介 U.S. officials on Monday approved the first long-acting drug to protect babies and young children against respiratory syncytial virus, or RSV. RSV sends...
The U.S. Food and Drug Administration has approved the first maternal vaccine intended to help protect newborns against respiratory syncytial virus (RSV).
The U.S. has approved the first vaccine for RSV, shots to protect older adults. The respiratory virus filled hospitals with wheezing babies last fall but also endangers seniors. After decades of failure in developing an RSV vaccine, the Food and Drug Adm
FDA approves RSV vaccine The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. 9 months ago What to know about the new vaccine for RSV ABC News chief medical correspondent Dr. Jen Ashton talks about promising data that shows an ...
Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study inThe Lancetconcluded the vaccine is 80% effective at preventing hospitalization due to complic...
Transmission electron micrograph of RSV. Credit: CDC/ Dr. Erskine Palmer / Public Domain The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any mRNA shot has been authorized against a disease other th...